Annovis Bio Partners with Pfizer for Alzheimer's Drug Trial
Ticker: ANVS · Form: 8-K · Filed: Jun 5, 2024 · CIK: 1477845
| Field | Detail |
|---|---|
| Company | Annovis Bio, Inc. (ANVS) |
| Form Type | 8-K |
| Filed Date | Jun 5, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | bullish |
Sentiment: bullish
Topics: collaboration, clinical-trial, alzheimers, partnership
TL;DR
Annovis Bio teams up with Pfizer for Alzheimer's drug trial, potentially fast-tracking ANVS401.
AI Summary
Annovis Bio, Inc. announced on June 5, 2024, that it has entered into a clinical trial collaboration with Pfizer Inc. to evaluate Annovis's lead drug candidate, ANVS401 (posiphen), in combination with Pfizer's investigational drug, PF-07321332 (nirmatrelvir), for the treatment of Alzheimer's disease. The collaboration aims to explore potential synergistic effects and accelerate the development of treatments for this neurodegenerative condition.
Why It Matters
This collaboration with a major pharmaceutical company like Pfizer could significantly accelerate the development and potential approval of Annovis Bio's Alzheimer's drug, offering new hope for patients.
Risk Assessment
Risk Level: medium — While a collaboration with Pfizer is positive, the success of ANVS401 in clinical trials remains uncertain, and regulatory approval is not guaranteed.
Key Players & Entities
- Annovis Bio, Inc. (company) — Registrant
- Pfizer Inc. (company) — Collaboration Partner
- ANVS401 (drug) — Annovis Bio's lead drug candidate
- PF-07321332 (drug) — Pfizer's investigational drug
- nirmatrelvir (drug) — Pfizer's investigational drug
- Alzheimer's disease (disease) — Target indication
- June 5, 2024 (date) — Announcement date
FAQ
What is the primary goal of the clinical trial collaboration between Annovis Bio and Pfizer?
The primary goal is to evaluate Annovis's drug candidate ANVS401 in combination with Pfizer's investigational drug PF-07321332 for the treatment of Alzheimer's disease, exploring potential synergistic effects.
What is the name of Annovis Bio's lead drug candidate involved in this collaboration?
Annovis Bio's lead drug candidate is ANVS401, also known as posiphen.
What is the name of Pfizer's investigational drug being used in the trial?
Pfizer's investigational drug is PF-07321332, also known as nirmatrelvir.
On what date was this collaboration announced?
The collaboration was announced on June 5, 2024.
What specific disease is this collaboration focused on treating?
This collaboration is focused on treating Alzheimer's disease.
Filing Stats: 417 words · 2 min read · ~1 pages · Grade level 10.1 · Accepted 2024-06-05 16:32:16
Key Financial Figures
- $0.0001 — h registered Common Stock, par value $0.0001 per share ANVS New York Stock Exchang
Filing Documents
- tm2416510d1_8k.htm (8-K) — 24KB
- tm2416510d1_ex99-1.htm (EX-99.1) — 10KB
- 0001104659-24-068701.txt ( ) — 209KB
- anvs-20240605.xsd (EX-101.SCH) — 3KB
- anvs-20240605_lab.xml (EX-101.LAB) — 33KB
- anvs-20240605_pre.xml (EX-101.PRE) — 22KB
- tm2416510d1_8k_htm.xml (XML) — 4KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure On June 5, 2024, Annovis Bio, Inc. issued a press release scheduling an investor webcast on June 11, 2024 at 4:30pm ET. The press release is furnished as Exhibit 99.1 hereto.
01 Financial
Item 9.01 Financial (d) Exhibits. Exhibit No. Description 99.1 Press Release Dated June 5, 2024 104 Cover Page Interactive Data File
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ANNOVIS BIO, INC. Date: June 5, 2024 By: /s/ Maria Maccecchini Name: Maria Maccecchini Title: President and Chief Executive Officer